JP2013543482A - Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置 - Google Patents

Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置 Download PDF

Info

Publication number
JP2013543482A
JP2013543482A JP2013520218A JP2013520218A JP2013543482A JP 2013543482 A JP2013543482 A JP 2013543482A JP 2013520218 A JP2013520218 A JP 2013520218A JP 2013520218 A JP2013520218 A JP 2013520218A JP 2013543482 A JP2013543482 A JP 2013543482A
Authority
JP
Japan
Prior art keywords
dopamine
dopa
treatment
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013520218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543482A5 (https=
Inventor
アレクサンダー ハウスン，パトリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytopharm Ltd
Original Assignee
Phytopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Ltd filed Critical Phytopharm Ltd
Publication of JP2013543482A publication Critical patent/JP2013543482A/ja
Publication of JP2013543482A5 publication Critical patent/JP2013543482A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2013520218A 2010-07-20 2011-07-20 Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置 Pending JP2013543482A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36601510P 2010-07-20 2010-07-20
US61/366,015 2010-07-20
PCT/GB2011/051376 WO2012010896A1 (en) 2010-07-20 2011-07-20 Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders

Publications (2)

Publication Number Publication Date
JP2013543482A true JP2013543482A (ja) 2013-12-05
JP2013543482A5 JP2013543482A5 (https=) 2014-09-04

Family

ID=44583771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013520218A Pending JP2013543482A (ja) 2010-07-20 2011-07-20 Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置

Country Status (13)

Country Link
US (1) US20130210786A1 (https=)
EP (1) EP2595621A1 (https=)
JP (1) JP2013543482A (https=)
KR (1) KR20130043197A (https=)
CN (1) CN103189056A (https=)
AU (1) AU2011281336B2 (https=)
BR (1) BR112013001422A2 (https=)
CA (1) CA2805693A1 (https=)
EA (1) EA201390070A1 (https=)
MX (1) MX2013000760A (https=)
SG (1) SG187090A1 (https=)
WO (1) WO2012010896A1 (https=)
ZA (1) ZA201301231B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017008044A (ja) * 2015-06-22 2017-01-12 学校法人 久留米大学 ドーパミンシグナル伝達の抑制剤
JP2023523119A (ja) * 2020-01-08 2023-06-02 ニューロヴェンティ カンパニー リミテッド リスリド化合物を有効成分として含む脆弱ｘ症候群または関連発達障害治療用組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
PL2854764T3 (pl) 2012-06-05 2019-07-31 Neuroderm Ltd Kompozycje zawierające apomorfinę i kwasy organiczne oraz ich zastosowania
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
CN105106230A (zh) * 2015-08-16 2015-12-02 南京华宽信息咨询中心 一种单胺氧化酶mao抑制剂及其应用
BR112022001595A2 (pt) * 2019-07-29 2022-03-22 Peptron Inc Composição farmacêutica para tratamento ou inibição da progressão da discinesia induzida por levodopa
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
MX2023000314A (es) * 2020-08-17 2023-02-22 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas de cannabinoides.
CN115282156A (zh) * 2022-09-05 2022-11-04 广东海洋大学 知母皂苷元在制备防治帕金森病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528370A (ja) * 2002-03-27 2005-09-22 フィトファーム・パブリック・リミテッド・カンパニー 治療方法ならびにサポゲニンおよびその誘導体の使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA985172A (en) 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
EP0102416A1 (en) 1982-08-23 1984-03-14 Nutrisearch Company Blends of egg albumen and whey protein of improved gel strength
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
KR930702000A (ko) * 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
CN1315473C (zh) 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
CN1131237C (zh) 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
BR9909110A (pt) * 1998-03-26 2000-12-12 Phytopharm Plc Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
GB9905275D0 (en) 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
DK1123094T3 (da) 1998-09-15 2007-08-20 Btg Int Ltd Terapeutiske præparater (II)
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
PL213697B1 (pl) * 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
US20070041924A1 (en) * 2005-08-19 2007-02-22 Bioderm Research Sebum Control Compositions Based on Saponins and Sapogenins
US20120034193A1 (en) * 2009-01-24 2012-02-09 Daryl Rees Treatment of neurotrophic factor mediated disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528370A (ja) * 2002-03-27 2005-09-22 フィトファーム・パブリック・リミテッド・カンパニー 治療方法ならびにサポゲニンおよびその誘導体の使用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017008044A (ja) * 2015-06-22 2017-01-12 学校法人 久留米大学 ドーパミンシグナル伝達の抑制剤
JP2023523119A (ja) * 2020-01-08 2023-06-02 ニューロヴェンティ カンパニー リミテッド リスリド化合物を有効成分として含む脆弱ｘ症候群または関連発達障害治療用組成物
JP7490064B2 (ja) 2020-01-08 2024-05-24 ニューロヴェンティ カンパニー リミテッド リスリード化合物を有効成分として含む脆弱ｘ症候群または関連発達障害治療用組成物

Also Published As

Publication number Publication date
EA201390070A1 (ru) 2013-09-30
MX2013000760A (es) 2013-10-28
ZA201301231B (en) 2014-04-30
SG187090A1 (en) 2013-02-28
KR20130043197A (ko) 2013-04-29
US20130210786A1 (en) 2013-08-15
CA2805693A1 (en) 2012-01-26
BR112013001422A2 (pt) 2019-09-24
CN103189056A (zh) 2013-07-03
WO2012010896A1 (en) 2012-01-26
AU2011281336A1 (en) 2013-01-31
AU2011281336B2 (en) 2015-03-05
EP2595621A1 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
JP2013543482A (ja) Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置
US20200268701A1 (en) Compositions and methods for producing elevated and sustained ketosis
JP2021522203A (ja) ベータ−ヒドロキシブチレートおよびアセトアセテートを用いたケト積重のための組成物および方法
HUE032486T2 (en) An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB)
MX2011007842A (es) Tratamiento de trastornos mediados por factores neurotroficos.
JP2019031504A (ja) トコトリエノールの経粘膜送達
JP2023153871A (ja) ５－ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法
JP2016104738A (ja) Ｎｏ供与体およびジチオランを含む組成物ならびに性機能の改善のためのそれらの使用
JP2018516934A (ja) 脂肪量を低減するためのβ−ヒドロキシ−β−メチルブチレート（ＨＭＢ）の組成物および使用方法
JP2009539942A (ja) ビフェプルノックス及びｌ−ｄｏｐａを含む組み合わせ製剤
KR101039818B1 (ko) 남성 갱년기에 의해 유발되는 질환의 예방 및/또는 치료를위한 카르니틴의 용도
JP2006516030A (ja) Ｃｏｐｄ及びその他の疾患に罹患した患者の状態を改善するための組成物及び方法
JP2009539941A (ja) Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤
JP7312286B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
CN110327321A (zh) 对饮酒导致中枢神经突触可塑性改变具有解救作用氨基酸的应用
WO2025085933A1 (en) Compositions and methods for treating gastrointestinal-related diseases and disorders
JP2015071583A (ja) 筋萎縮抑制剤
JPWO2020080398A1 (ja) アルコール飲料摂取による悪酔い又は二日酔いの抑制剤
TW200813038A (en) Combination preparations comprising SLV308 and L-DOPA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151117